Hopkinton phasedown a drag in 2013

Hopkinton phasedown hits Lonza's 2013 sales

Higher earnings and improved margins did not impress investors in Lonza, which saw its share price tumble today after revealing that sales to the drug sector fell in 2013.

CRL pushes deeper into an increasingly lucrative Asia

Charles River expands presence in Asia with acquisition

By Zachary Brennan

Early stage drug developer Charles River Laboratories is pushing further into Asia with its purchase of the microbiology subcontractor BRASS Pte Ltd. Terms of the acquisition were not disclosed.

More ALS research on the way

Evotec, Harvard Form ALS Research Partnership

German CRO Evotec and the Harvard Stem Cell Institute have partnered to discover compounds that might prevent or slow ALS (amyotrophic lateral sclerosis) and other motor-neuron diseases.


Follow us


View more


Featured Suppliers

All suppliers